A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Clinical trial NCT05525247 · TERMINATED

Trial details

NCT number: NCT05525247
Sponsor: Selecxine
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2022-12-21
Primary completion: 2025-08-26
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.